Gene therapy for the treatment of pituitary tumors

References

• Melmed S. Mechanisms of pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest.112, 1603–1618 (2003).
   PubMed Web of Science ®Google Scholar
• Burek JD. Pathology of Aging Rats. CRC Press, Boca Raton, FL, USA (1978).
   Google Scholar
• Monson JP. The epidemiology of endocrine tumours. Endocr. Relat. Cancer7, 29–36 (2000).
   PubMedGoogle Scholar
• Arafah BM, Nasralllah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr. Relat. Cancer8, 287–305 (2001).
   PubMed Web of Science ®Google Scholar
• Swensen R, Kirsch W. Brain neoplasms in women: a review. Clin. Obstet. Gynecol.45, 904–927 (2002).
   PubMedGoogle Scholar
• Melmed S, Kleinberg D. Anterior pituitary. In: Williams Textbook of Endocrinology (11th Edition). Kornenberg HM, Melmed S, Polonsky KS, Larsen PR (Eds). Saunders–Elsevier, Philadelphia, PA, USA 155–261 (2008).
   Google Scholar
• Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab.90, 3089–3099 (2005).
   PubMed Web of Science ®Google Scholar
• Shimon I, Melmed S. Management of pituitary tumors. Annals Int. Med.129, 472–483 (1998).
   PubMed Web of Science ®Google Scholar
• Melmed S. General aspects of the management of pituitary tumors by surgery or radiation therapy. In: Endocrinology. DeGroot LJ (Ed.). Saunders, PA, USA, 497–503 (1997).
   Google Scholar
• Sudhakar N, Ray A, Vafidis JA. Complications after transsphenoidal surgery: our experience and a review of the literature. Br. J. Neurosurg.18, 507–512 (2004).
   PubMed Web of Science ®Google Scholar
• Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ169, 575–581 (2003).
   PubMed Web of Science ®Google Scholar
• Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med.331, 904–909 (1994).
   PubMed Web of Science ®Google Scholar
• Sheppard MC. Aims of treatment and definition of cure. In: Treating Acromegaly – 100 Years On. Wass JAH (Ed.). Society for Endocrinology, Bristol, UK 17–31 (1994).
   Google Scholar
• Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab.90, 1856–1863 (2005).
   PubMed Web of Science ®Google Scholar
• Sutton ML. Adult central nervous system. In: The Radiotherapy of Malignant Disease. Easson EC, Pointon RCS (Eds). Springer, NY, USA, 215–236 (1985).
   Google Scholar
• Grigsby PW, Sheline GE. Pituitary. In: Principles and Practice of Radiation Oncology. Perez CA, Bray LA. (Eds). Lippincott, PA, USA 564–582 (1990).
   Google Scholar
• Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane JA Jr, Oskouian R. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J. Neurooncol.69, 257–272 (2004).
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science275, 1320–1323 (1997).
   PubMed Web of Science ®Google Scholar
• Hidaka C, Milano E, Leopold PL et al. CAR – dependent and CAR-independent pathways of adenovirus vector – mediated gene transfer and expression in human fibroblast. J. Clin. Invest.103, 579–587 (1999).
   PubMedGoogle Scholar
• Hitt M, Bett AJ, Addison CL, Prevec L, Graham FL. Techniques for human adenovirus vector construction and characterization. Methods Mol. Genet.7, 13–30 (1995).
   Google Scholar
• Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci. USA91, 4407–4411 (1994).
   PubMed Web of Science ®Google Scholar
• Park JS, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl Acad. Sci. USA93, 13565–13570 (1996).
   PubMedGoogle Scholar
• Parks RJ, Graham FL. A helper-dependant system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol.71, 3293–3298 (1997).
   PubMedGoogle Scholar
• Ideguchi M, Kajiwara K, Yoshikawa K, Uchida T, Ito H. Local adenovirus-mediated CTLA4–immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience95, 217–226 (2000).
   PubMedGoogle Scholar
• Geddes BJ, Harding TC, Hughes DS et al. Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: suppression of the immune response with cyclosporin. Endocrinology137, 5166–5169 (1996).
   PubMedGoogle Scholar
• Ilan Y, Prakash R, Davidson A et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J. Clin. Invest.99, 1098–1106 (1997).
   PubMedGoogle Scholar
• Roizman B. The function of herpes simplex virus genes: a primer for genetic enginneering of novel vectors. Proc. Natl Acad. Sci. USA93, 11307–11312 (1996).
   PubMed Web of Science ®Google Scholar
• Wolfe D, Goins WF, Yamada M et al. Engineering herpes simplex virus vectors for CNS applications. Exp. Neurol.159, 34–46 (1999).
   PubMed Web of Science ®Google Scholar
• Tomasec P, Bain D, Castro MG, Preston CM, Lowenstein PR. Herpes simplex virus temperature-sensitive mutant tsK as a vector for neuronal gene transfer. In: Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders. Lowenstein PR, Enquist LW (Eds). Wiley, Chichester, UK 169–186 (1996).
   Google Scholar
• Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods33, 164–172 (2004).
   PubMed Web of Science ®Google Scholar
• Vogel R, Amar L, Thi AD, Saillour P, Mallet J. A single lentivirus vector mediates doxycycline-regulated expression of transgenes in the brain. Hum. Gene Ther.15, 157–165 (2004).
   PubMedGoogle Scholar
• Li Z, Dullmann J, Schiedlmeier B et al. Murine leukemia induced by retroviral gene marking. Science296, 497 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet.4, 346–358 (2003).
   PubMed Web of Science ®Google Scholar
• Castro MG, Goya RG, Sosa YE et al. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology138, 2184–2194 (1997).
   PubMedGoogle Scholar
• Goya RG, Rowe J, Sosa YE, Tomasec P, Lowenstein PR, Castro MG. Use of recombinant herpes simplex virus type I vectors for gene transfer into tumour and normal anterior pituitary cells. Mol. Cell. Endocrinol.139, 199–207 (1998).
   PubMedGoogle Scholar
• Davis JR, McMahon RF, Lowenstein PR, Castro MG, Lincoln GA, McNeilly AS. Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis. J. Endocrinol.173, 265–271 (2002).
   PubMedGoogle Scholar
• Lee EJ, Thimmapaya B, Jameson JL. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: implications for gene therapy. Neurosurgery46, 1461–1469 (2000).
   PubMed Web of Science ®Google Scholar
• Bolognani F, Albariño C, Romanowski V, Carri NG, Goya RG. In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion. Eur. J. Endocrinol.145, 497–503 (2001).
   PubMedGoogle Scholar
• Carri NG, Sosa YE, Brown OA, Albarino C, Romanowski V, Goya RG. Studies on in vivo gene transfer in pituitary tumors using herpes-derived and adenoviral vectors. Brain. Res. Bull.65, 17–22 (2005).
   PubMedGoogle Scholar
• Roche C, Zamora AJ, Taieb D et al. Lentiviral vectors efficiently transduce human gonadotroph and somatotroph adenomas in vitro. Targeted expression of transgene by pituitary hormone promoters. J. Endocrinol.183, 217–233 (2004).
   PubMedGoogle Scholar
• Windeatt S, Southgate TD, Dewey RA et al. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. J. Clin. Endocr. Metab.85, 1296–1305 (2000).
   PubMedGoogle Scholar
• Lee EJ, Anderson LM, Thimmapaya B, Jameson JL. Targeted expresion of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J. Clin. Endocrinol. Metab.84, 786–794 (1999).
   PubMedGoogle Scholar
• Southgate TD, Windeatt S, Smith-Arica J. et al. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. Endocrinology141, 3493–3505 (2000).
   PubMedGoogle Scholar
• Southgate TD, Stone D, Williams JC, Lowenstein PR, Castro MG. Long-term transgene expression within the anterior pituitary gland in situ: impact on circulating hormone levels, cellular and antibody-mediated immune responses. Endocrinology142, 464–476 (2001).
   PubMedGoogle Scholar
• Paquin A, Jaalouk DE, Galipeau J. Retrovector encoding a green fluorescent protein–herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum. Gene Ther.12, 13–23 (2001).
   PubMed Web of Science ®Google Scholar
• Cónsole G, Hereñú CB, Camihort GA, Luna GC, Bracamonte MI, Goya RG. Insulin-like growth factor-I gene therapy reduces hyperprolactinemia and reverses morphologic changes in experimental rat prolactinomas. Mol. Cancer7, 13–18 (2008).
   PubMed Web of Science ®Google Scholar
• Lee EJ, Jameson JL. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum. Gene Ther.13, 533–542 (2002).
   PubMedGoogle Scholar
• Candolfi M, Jaita G, Pisera D et al. Adenoviral vectors encoding tumor necrosis factor-α and FasL induce apoptosis of normal and tumoral anterior pituitary cells. J. Endocrinol.189, 681–690 (2006).
   PubMedGoogle Scholar
• Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 δ20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene9, 1021–1029 (1994).
   PubMedGoogle Scholar
• Riley DJ, Yu A, Lee WH. Adenovirus-mediated retinoblastoma gene therapy supresses spontaneous pituitary melanotroph tumors in Rb+/- mice. Nature Med.2, 1316–1321 (1996).
   PubMed Web of Science ®Google Scholar
• Webster J, Ham J, Bevan J, Scalon M . Growth factors and pituitary tumors. Trends Endocrinol. Metab.1, 85–98 (1989).
   Google Scholar
• Halper J, Parnel P, Carter B, Ren P, Scheithauer B. Presence of growth factors in human pituitary. Lab. Invest.66, 639–645 (1992).
   PubMed Web of Science ®Google Scholar
• Houben H, Denef C. Bioactive peptides in anterior pituitary cells. Peptides15, 547–582 (1994).
   PubMedGoogle Scholar
• D´Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl Acad. Sci. USA81, 935–939 (1984).
   PubMedGoogle Scholar
• Console GM, Hereñú CB, Camihort GA, Luna GC, Ferese C, Goya RG. Effect of insulin-like growth factor-I gene therapy on the somatotropic axis in experimental prolactinomas. Cells Tissues Organs DOI: 10.1159/000166609 (2009) (Epub ahead of print).
   Google Scholar
• Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc. Natl Acad. Sci USA88, 5547–5551 (1992).
   Google Scholar
• Smith-Arica JR, Williams JC, Stone D, Smith J, Lowenstein PR, Castro MG. Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo. Endocrinology142, 2521–2532 (2001).
   PubMedGoogle Scholar
• Williams JC, Stone D, Smith-Arica JR, Morris ID, Lowenstein PR, Castro MG. Regulated adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Mol. Ther.4, 593–602 (2001).
   PubMedGoogle Scholar
• Reggiani PC, Hereñú CB, Rimoldi OJ et al. Gene therapy for long-term restoration of circulating thymulin in thymectomized mice and rats. Gene Ther.13, 1214–1221 (2006).
   PubMedGoogle Scholar
• Morel GR, Brown OA, Reggiani PC et al. Peripheral and mesencephalic transfer of a synthetic gene for the thymic peptide thymulin. Brain Res. Bull.69, 647–651 (2006).
   PubMedGoogle Scholar
• Freese A, During MJ, Davidson BL et al. Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release. J. Clin. Endocrinol. Metab.81, 2401–2404 (1996).
   PubMedGoogle Scholar
• Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q. J. Med.70, 145–160 (1991).
   Google Scholar
• Castro MG, Southgate T, Lowenstein PR. Molecular therapy in a model of neuroendocrine disease: developing clinical gene therapy for pituitary tumours. Trends Endocrinol. Metab.12, 58–64 (2001).
   PubMedGoogle Scholar
• Hoganson DK, Batra RK, Olsen JC, Boucher RC. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res.56, 1315–1323 (1996).
   PubMed Web of Science ®Google Scholar
• Aoki T, Kato S, Fox JC, Okamoto K, Morimatsu M, Shigemori M. Inhibition of autocrine fibroblast growth factor signaling by the adenovirus-mediated expression of an antisense transgene or a dominant negative receptor in human glioma cells. Int.J. Oncol.21, 629–636 (2002).
   PubMedGoogle Scholar
• Goya RG, Sarkar DK, Brown OA, Hereñú CB. Potential of gene therapy for the treatment of pituitary tumors. Curr. Gene Ther.4, 79–87 (2004).
   PubMed Web of Science ®Google Scholar